BridgeBio Pharma, Inc.
BBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001743881
In the last 90 days, BridgeBio Pharma, Inc. insiders filed 0 open-market purchases and 5 sales; 512 institutions reported holding it in 13F filings for Q2 2026, worth $17.3B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $19.2M in total
- 5
- 13F holdersQ2 2026, +18 vs. previous quarter
- 512
- 13F valueReported value at the end of Q2 2026
- $17.3B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding BBIO, Q2 2026
1 superinvestor reports holding BridgeBio Pharma, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
2.1%
BridgeBio Pharma, Inc.'s share of the portfolio
- Shares
- 9,949,219
- Value
- $741.0M
Latest insider trades
Open-market purchases and sales by BridgeBio Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 (view filing)6:21 PM ET | Sep 17 | 4 days | Kumar NeilChief Executive Officer | SSale | −10.0K | $69.08 | −$690.8K | −2.0%495.7K after | 2 lots10b5-1 |
| Aug 20, 2026 (view filing)4:31 PM ET | Aug 18 | 2 days | Kumar NeilChief Executive Officer | SSale | −35.0K | $82.53 | −$2.89M | −12.6%243.3K after | 4 lots10b5-1 |
| Aug 20, 2026 (view filing)4:31 PM ET | Aug 19 | 1 day | Kumar NeilChief Executive Officer | SSale | −10.0K | $84.03 | −$840.3K | −1.9%505.7K after | 3 lots10b5-1 |
| Aug 3, 2026 (view filing)4:20 PM ET | Jul 30 | 4 days | Apuli MaricelChief Accounting Officer | SSale | −2.00K | $80.06 | −$160.1K | −1.5%127.4K after | 10b5-1 |
| Jul 13, 2026 (view filing)4:41 PM ET | Jul 9 | 4 days | Ellis AndreaDirector | SSale | −17.2K | $84.00 | −$1.44M | −43.2%22.6K after | 10b5-1 |
| Jul 13, 2026 (view filing)4:40 PM ET | Jul 9 | 4 days | Cook Jennifer E.Director | SSale | −148.6K | $88.54 | −$13.2M | −94.7%8.38K after | 2 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 23-24 | 1 day | Cook Jennifer E.Director | SSale | −39.4K | $69.92 | −$2.75M | −82.4%8.38K after | 2 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22-23 | 2 days | Valantine HannahDirector | SSale | −5.00K | $68.25 | −$341.5K | −35.1%9.26K after | 2 lots10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Cook Jennifer E.Director | SSale | −90.2K | $66.63 | −$6.01M | −93.2%6.59K after | 2 lots10b5-1 |
| Jun 8, 2026 (view filing) | Jun 4-5 | 4 days | Kumar NeilChief Executive Officer | SSale | −80.0K | $67.67 | −$5.41M | −1.8%4.32M after | 14 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in BridgeBio Pharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 14,110,278 | $1.05B | 0.43% | +14,110,278 | New |
| Kohlberg Kravis Roberts & Co. L.P. | 13,260,971 | $988.3M | 17.31% | 00.0% | Unchanged |
| BlackRock, Inc. | 10,287,156 | $823.8M | 0.01% | −3,920,601−27.6% | Reduced |
| Farallon Capital Management, L.L.C. | 10,743,063 | $800.1M | 4.68% | +1,377,600+14.7% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 9,949,219 | $741.0M | 2.11% | −1,893,215−16.0% | Reduced |
| Vanguard Capital Management LLC | 7,898,973 | $588.3M | 0.01% | +139,478+1.8% | Added |
| Vanguard Portfolio Management LLC | 7,656,722 | $570.3M | 0.03% | −423,851−5.2% | Reduced |
| Wellington Management Group LLP | 5,308,924 | $405.2M | 0.07% | +2,824,971+113.7% | Added |
| State Street Corp | 4,435,932 | $402.7M | 0.01% | −498,388−10.1% | Reduced |
| Two Sigma Investments, LP | 4,722,185 | $351.7M | 0.26% | +1,601,554+51.3% | Added |